Pfizer Inc. (NYSE:PFE) Holdings Trimmed by Mizuho Securities USA LLC

Key Points

• Mizuho Securities USA LLC reduced its stake in **Pfizer Inc.** by **15.5%**, holding **453,755 shares** worth approximately **$11.50 million** after selling **83,347 shares** in the first quarter.
• Pfizer reported **earnings per share** of **$0.78**, exceeding analysts' expectations of **$0.58**, along with a **10.3% increase** in quarterly revenue compared to the previous year.
• The company announced a quarterly dividend of **$0.43 per share**, representing a **7.0% yield**, with a **payout ratio** of **91.49%**.

Mizuho Securities USA LLC lowered its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 15.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 453,755 shares of the biopharmaceutical company's stock after selling 83,347 shares during the period. Mizuho Securities USA LLC's holdings in Pfizer were worth $11,498,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of PFE. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. F M Investments LLC raised its holdings in shares of Pfizer by 15.9% during the fourth quarter. F M Investments LLC now owns 94,051 shares of the biopharmaceutical company's stock valued at $2,495,000 after buying an additional 12,895 shares during the last quarter. Phoenix Financial Ltd. raised its holdings in shares of Pfizer by 1.1% during the fourth quarter. Phoenix Financial Ltd. now owns 67,490 shares of the biopharmaceutical company's stock valued at $1,791,000 after buying an additional 764 shares during the last quarter. Finally, Kennedy Capital Management LLC raised its holdings in shares of Pfizer by 24.1% during the fourth quarter. Kennedy Capital Management LLC now owns 206,886 shares of the biopharmaceutical company's stock valued at $5,489,000 after buying an additional 40,193 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Pfizer stock traded up $0.34 during mid-day trading on Friday, hitting $24.57. The company's stock had a trading volume of 36,356,648 shares, compared to its average volume of 46,490,120. The company has a quick ratio of 0.96, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $139.69 billion, a P/E ratio of 13.07, a P/E/G ratio of 0.89 and a beta of 0.52. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The stock's fifty day moving average price is $24.44 and its two-hundred day moving average price is $24.49.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.60 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer's payout ratio is 91.49%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. HSBC cut their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Morgan Stanley lifted their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Finally, BMO Capital Markets dropped their target price on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.